These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 12732682

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi.
    Kennel SJ, Boll R, Stabin M, Schuller HM, Mirzadeh S.
    Br J Cancer; 1999 Apr; 80(1-2):175-84. PubMed ID: 10389994
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
    Huber R, Seidl C, Schmid E, Seidenschwang S, Becker KF, Schuhmacher C, Apostolidis C, Nikula T, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
    [Abstract] [Full Text] [Related]

  • 6. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.
    J Nucl Med; 2005 Dec 01; 46(12):2061-7. PubMed ID: 16330571
    [Abstract] [Full Text] [Related]

  • 7. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.
    J Nucl Med; 2009 Oct 01; 50(10):1700-8. PubMed ID: 19793735
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J, Andersson H, Bernhardt P, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1228-37. PubMed ID: 17145538
    [Abstract] [Full Text] [Related]

  • 10. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A.
    Nucl Med Biol; 2005 Oct 15; 32(7):741-7. PubMed ID: 16243650
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotherapy using vascular targeted 213Bi: the role of tumor necrosis factor alpha in the development of pulmonary fibrosis.
    Davis IA, Kennel SJ.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3160s-3164s. PubMed ID: 10541358
    [Abstract] [Full Text] [Related]

  • 12. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
    Kennel SJ, Mirzadeh S, Eckelman WC, Waldmann TA, Garmestani K, Yordanov AT, Stabin MG, Brechbiel MW.
    Radiat Res; 2002 Jun 15; 157(6):633-41. PubMed ID: 12005541
    [Abstract] [Full Text] [Related]

  • 13. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.
    Akabani G, McLendon RE, Bigner DD, Zalutsky MR.
    Int J Radiat Oncol Biol Phys; 2002 Nov 15; 54(4):1259-75. PubMed ID: 12419456
    [Abstract] [Full Text] [Related]

  • 14. A model of cell inactivation by alpha-particle internal emitters.
    Humm JL, Chin LM.
    Radiat Res; 1993 May 15; 134(2):143-50. PubMed ID: 8488249
    [Abstract] [Full Text] [Related]

  • 15. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells.
    Kennel SJ, Stabin M, Roeske JC, Foote LJ, Lankford PK, Terzaghi-Howe M, Patterson H, Barkenbus J, Popp DM, Boll R, Mirzadeh S.
    Radiat Res; 1999 Mar 15; 151(3):244-56. PubMed ID: 10073661
    [Abstract] [Full Text] [Related]

  • 16. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.
    Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M.
    Cancer Res; 1992 Oct 15; 52(20):5818-20. PubMed ID: 1394209
    [Abstract] [Full Text] [Related]

  • 17. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.
    J Nucl Med; 2009 Jul 15; 50(7):1153-60. PubMed ID: 19525452
    [Abstract] [Full Text] [Related]

  • 18. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
    Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF, Nikula TK, Seidl C, Becker I, Miederer M, Apostolidis C, Adam C, Huber R, Kremmer E, Fischer K, Schwaiger M.
    Cancer Res; 2001 Apr 01; 61(7):2804-8. PubMed ID: 11306447
    [Abstract] [Full Text] [Related]

  • 19. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
    Yao Z, Garmestani K, Wong KJ, Park LS, Dadachova E, Yordanov A, Waldmann TA, Eckelman WC, Paik CH, Carrasquillo JA.
    J Nucl Med; 2001 Oct 01; 42(10):1538-44. PubMed ID: 11585870
    [Abstract] [Full Text] [Related]

  • 20. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis.
    Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL.
    Radiat Res; 1992 May 01; 130(2):220-6. PubMed ID: 1574578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.